Results 141 to 150 of about 157,698,581 (270)

Immunity to melanoma in mice immunized with IL-2-secreting mouse fibroblasts expressing melanoma antigens.

open access: yes, 1994
Immunity to melanoma in mice immunized with IL-2-secreting mouse fibroblasts expressing melanoma ...
Tae Sung. Kim (7950254)
core   +2 more sources

Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A self‐assembling peptide–adjuvant conjugate links neoantigens to TLR7 agonism, forming cationic nanoparticles that enhance lymph‐node retention, dendritic‐cell activation, and antitumor T‐cell immunity. This chemically defined platform shows how synchronized antigen and innate stimulation can be adapted across melanoma, bladder cancer, and triple ...
Yang‐Fan Wu   +15 more
wiley   +1 more source

Non‐Invasively Quantitative Raman Imaging for Calculation of Lymphatic Transport Kinetics of Micelles in Mice

open access: yesAdvanced Science, EarlyView.
Non‐invasively quantitative Raman imaging with stacking‐induced charge transfer‐enhanced Raman scattering (SICTERS) enables accurate measurement of concentrations and pharmacokinetic modeling of lymphatic transport of micelles in mice. This platform allows dynamic analysis of nanoparticle transport and underpins the design of effective lymph node ...
Yunlu Li   +6 more
wiley   +1 more source

Collagen‐Binding IL‐15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self‐Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
Repurposing the dense tumor stroma from a physical barrier into an anchoring scaffold, an engineered oncolytic adenovirus encoding IL15C‐CBD overcomes the immunosuppressive microenvironment in triple‐negative breast cancer. Intratumoral viral replication secretes this collagen‐anchored immunocytokine, forming a localized cytokine depot.
Yaqi Yang   +14 more
wiley   +1 more source

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

open access: yesAdvanced Science, EarlyView.
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami   +7 more
wiley   +1 more source

Nuclear IDH3A Drives Transcriptional Programs in Melanoma via the YBX1–JUN/FOS Axis

open access: yesAdvanced Science, EarlyView.
Genomic amplification drives aberrant nuclear localization of IDH3A in melanoma. Independent of its canonical metabolic activity, nuclear IDH3A cooperates with YBX1 to activate the c‐JUN/c‐FOS transcriptional program, while NONO facilitates its nuclear localization.
Juan Ran   +10 more
wiley   +1 more source

Distal Free‐Edge and Periungual Dermoscopic Features Distinguishing Pigmented Nail Unit Melanoma From Benign Melanonychia: A Retrospective Study in an Asian Population

open access: yesDermatologic Therapy
Pigmented nail unit melanoma (NUM) often presents as longitudinal melanonychia and may mimic benign melanonychia, especially in Asian populations. We conducted a retrospective study at a tertiary medical center in Taiwan between 2011 and 2025 to identify
Hsin-Yi Huang   +4 more
doaj   +1 more source

Asymmetric Structure‐Driven Functional Synergy: A Multistimuli‐Activated Janus Nanomotor for Self‐Amplifying NO Cascade Therapy

open access: yesAdvanced Science, EarlyView.
The Janus nanomotors leverage an “asymmetric structure‐driven functional synergy” strategy to orchestrate spatiotemporally coordinated catalytic functions, in situ self‐amplifying NO generation, and deep tumor penetration, thereby enabling controllable, sustained, and uniform NO generation within the tumor microenvironment.
Chengcheng Li   +6 more
wiley   +1 more source

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

open access: yesJournal for ImmunoTherapy of Cancer
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma.
Dirk Schadendorf   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy